^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LPCAT2 (Lysophosphatidylcholine Acyltransferase 2)

    i
    Other names: LPCAT2, Lysophosphatidylcholine Acyltransferase 2, LysoPAFAT, AGPAT11, AYTL1, Acetyl-CoA:Lyso-Platelet-Activating Factor Acetyltransferase, 1-Alkenylglycerophosphocholine O-Acyltransferase, 1-Alkylglycerophosphocholine O-Acetyltransferase, 1-Acylglycerol-3-Phosphate O-Acyltransferase 11, 1-Acylglycerophosphocholine O-Acyltransferase, Lysophosphatidic Acid Acyltransferase Alpha, Acetyl-CoA:Lyso-PAF Acetyltransferase, Lysophospholipid Acyltransferase 9, Lyso-PAF Acetyltransferase, 1-AGP Acyltransferase 11, LysoPC Acyltransferase 2, Acyltransferase-Like 1, LPC Acyltransferase 2, LPAAT-Alpha, 1-AGPAT 11, FLJ20481, LPCAT-2, LPLAT9, Lyso-Platelet-Activating Factor (PAF) Acetyltransferase, Acyl-CoA:Lysophosphatidylcholine Acyltransferase 2, Acyltransferase Like 1
    Associations

    News

    Trials
    over1year
    Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors. (PubMed, Proc Natl Acad Sci U S A)
    Lysophosphatidylcholine acyltransferase 2 (LPCAT2), the PAF biosynthetic enzyme, is up-regulated in human pancreatic ductal adenocarcinoma (PDAC) and shows an unfavorable correlation with patient survival across multiple cancer types. Our study identifies PAF as a lipid-driven mechanism of MDSC differentiation in the TME, providing a potential target for cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TNFRSF10A (TNF Receptor Superfamily Member 10a) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2)
    over1year
    LPCAT2-mediated lipid droplet production supports pancreatic cancer chemoresistance and cell motility. (PubMed, Int Immunopharmacol)
    Since chemoresistance towards gemcitabine (GEM) is an obstacle for clinical therapy of pancreatic cancer, we sought to investigate the contribution of LD accumulation to GEM resistance...Both LPCAT2 downregulation and triacsin C reversed the STAT5B-induced potentiation of malignant phenotypes in pancreatic cancer cells. In conclusion, LPCAT2-mediated lipid droplet production supported pancreatic cancer chemoresistance and cell motility, which was triggered by STAT5B.
    Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B) • PLIN2 (Perilipin) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2)
    |
    gemcitabine
    almost2years
    LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis. (PubMed, Oncogene)
    Altogether, we elucidated that LPCAT2 suppresses SLC7A11 expression by inhibiting PRMT1 nuclear translocation, thereby inducing ferroptosis in CRC cells. Moreover, inhibitors of the PRMT1/SLC7A11 axis could delay tumor progression in CRC with low LPCAT2 expression, making it a potentially effective treatment for CRC.
    Journal
    |
    PRMT1 (Protein Arginine Methyltransferase 1) • SLC7A11 (Solute Carrier Family 7 Member 11) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2)
    |
    SLC7A11 expression
    over2years
    AKR1B1 and LPCAT2 act as potential biomarkers of neoadjuvant chemoradiotherapy in locally advanced rectal cancer (ESSO 2023)
    On the other hand, AKR1B1 appears to have a role as a factor that is resistant or less responsive to radiotherapy. AKR1B1 factor could be used to identify patients who are less likely to respond favorably to nCRT, allowing for better personalized treatment approaches.
    Clinical • IO biomarker • Metastases
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2)
    over2years
    Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood ETV6::RUNX1+ and High Hyperdiploid Acute Lymphoblastic Leukemia. (PubMed, Hemasphere)
    We detected 3 novel fusion genes (SFMBT2::DGKD, PDS5B::STAG2, and TDRD5::LPCAT2), for which the sequence and expression were validated by long-read and whole transcriptome sequencing, respectively. OGM and WES identified double hits of SVs and SNVs (ETV6, BTG1, STAG2, MANBA, TBL1XR1, NSD2) in the same patient demonstrating the power of the combined approach to define the landscape of genomic alterations in BCP-ALL.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • STAG2 (Stromal Antigen 2) • CD4 (CD4 Molecule) • DGKD (Diacylglycerol Kinase Delta) • DRD5 (Dopamine Receptor D5) • GPRC5A (G Protein-Coupled Receptor Class C Group 5 Member A) • IKBKB (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta) • LPCAT2 (Lysophosphatidylcholine Acyltransferase 2) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SFMBT2 (Scm Like With Four Mbt Domains 2) • TBL1XR1 (TBL1X Receptor 1)
    |
    IKZF1 deletion